Replimune Group Inc’s recently made public that its Chief Executive Officer Patel Sushil unloaded Company’s shares for reported $0.12 million on Dec 16 ’24. In the deal valued at $12.42 per share,10,000 shares were sold. As a result of this transaction, Patel Sushil now holds 202,014 shares worth roughly $1.52 million.
Then, Sushil Patel bought 15,000 shares, generating $188,550 in total proceeds.
Before that, Xynos Konstantinos sold 7,246 shares. Replimune Group Inc shares valued at $78,112 were divested by the Chief Medical Officer at a price of $10.78 per share. As a result of the transaction, Xynos Konstantinos now holds 109,885 shares, worth roughly $0.82 million.
ROTH MKM initiated its Replimune Group Inc [REPL] rating to a Buy in a research note published on August 28, 2024; the price target was $17. Piper Sandler began covering REPL with “an Overweight” recommendation on November 19, 2021.
Price Performance Review of REPL
On Tuesday, Replimune Group Inc [NASDAQ:REPL] saw its stock fall -25.07% to $7.50. Over the last five days, the stock has lost -20.13%. Replimune Group Inc shares have fallen nearly -38.07% since the year began. Nevertheless, the stocks have risen 14.33% over the past one year. While a 52-week high of $17.00 was reached on 02/21/25, a 52-week low of $4.92 was recorded on 04/09/25. SMA at 50 days reached $9.98, while 200 days put it at $11.29.
Levels Of Support And Resistance For REPL Stock
The 24-hour chart illustrates a support level at 6.66, which if violated will result in even more drops to 5.82. On the upside, there is a resistance level at 9.15. A further resistance level may holdings at 10.80. The Relative Strength Index (RSI) on the 14-day chart is 34.84, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.20, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.94%. Stochastics %K at 61.46% indicates the stock is a holding.
The most recent change occurred on November 17, 2020 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $60 price target.
